These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36656510)

  • 1. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
    Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
    BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
    Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
    Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
    Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
    Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
    Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
    Yi X; Hu S; Ma M; Huang D; Zhang Y
    Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis.
    Liu M; Xiang Q; Dai F; Yuan Y; Wu Z; Xiang T
    Clin Breast Cancer; 2024 Oct; 24(7):575-584.e1. PubMed ID: 38821742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Ilie SM; Briot N; Constantin G; Roussot N; Ilie A; Bergeron A; Arnould L; Beltjens F; Desmoulin I; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Amet A; Coutant C; Coudert B; Bertaut A; Ladoire S
    Breast Cancer; 2023 Nov; 30(6):997-1007. PubMed ID: 37561255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.
    Guan D; Shi Q; Zheng Y; Zheng C; Meng X
    Clin Breast Cancer; 2024 Jul; 24(5):463-472.e2. PubMed ID: 38744585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National Cancer Database Analysis.
    Zhong G; Song D; Lou W; Wei B; Chen Y; Cui H; Hu J; Dong H; Chen J; Dai Z
    Eur J Surg Oncol; 2023 Nov; 49(11):106970. PubMed ID: 37365055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    Xia LY; Cao XC; Yu Y
    World J Surg Oncol; 2024 Apr; 22(1):106. PubMed ID: 38643188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.